These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 10697504)

  • 1. Cytosolic p53 protein and serum p53 autoantibody evaluation in breast cancer. Comparison with prognostic factors.
    Dalifard I; Daver A; Larra F
    Anticancer Res; 1999; 19(6B):5015-22. PubMed ID: 10697504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
    Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
    Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of p53 autoantibodies in the serum of patients with breast cancer.
    Willsher PC; Pinder SE; Robertson L; Nicholson RI; Ellis IO; Bell JA; Blamey RW; Green JA; Robertson JF
    Anticancer Res; 1996; 16(2):927-30. PubMed ID: 8687153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.
    Lenner P; Wiklund F; Emdin SO; Arnerlöv C; Eklund C; Hallmans G; Zentgraf H; Dillner J
    Br J Cancer; 1999 Feb; 79(5-6):927-32. PubMed ID: 10070892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of TP53 protein accumulation in human primary breast cancer: an analysis by luminometric immunoassay on 1491 tumor cytosols.
    Berns EM; De Witte HH; Klijn JG; Willman K; Look MP; Meijer-Van Gelder ME; Benraad TJ; Foekens JA
    Anticancer Res; 1997; 17(4B):3003-6. PubMed ID: 9329586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
    Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
    Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
    Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic value of antibodies against p53 in patients with oral squamous cell carcinoma--five years survival rate].
    Hofele C; Schwager-Schmitt M; Volkmann M
    Laryngorhinootologie; 2002 May; 81(5):342-5. PubMed ID: 12001023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast.
    Regele S; Kohlberger P; Vogl FD; Böhm W; Kreienberg R; Runnebaum IB
    Br J Cancer; 1999 Oct; 81(4):702-4. PubMed ID: 10574259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC; Lin JK; Lin TC; Liang WY
    Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
    Shao ZM; Wu J; Shen ZZ; Nguyen M
    Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
    Riisbro R; Christensen IJ; Piironen T; Greenall M; Larsen B; Stephens RW; Han C; Høyer-Hansen G; Smith K; Brünner N; Harris AL
    Clin Cancer Res; 2002 May; 8(5):1132-41. PubMed ID: 12006529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
    Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
    Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
    Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
    Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
    Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
    Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
    Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical localization and correlation of p53 and PCNA expression in breast carcinoma.
    Goel MM; Goel R; Mehrotra A; Nath P; Agarwal PK; Singh K; Mehrotra R
    Indian J Exp Biol; 2000 Mar; 38(3):225-30. PubMed ID: 10927863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.